Pfizer cuts five biosimilar candidates and 150 jobs in R&D shakeup
Pfizer has chosen to drop five biosimilar candidates and 150 jobs to divert the funds into developing its late-stage pipeline.
Pfizer has chosen to drop five biosimilar candidates and 150 jobs to divert the funds into developing its late-stage pipeline.
Sanofi and BioNTech are extending a research agreement from 2015 as the collaboration’s jointly developed mRNA therapy enters clinical testing.